The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 10
- 主要终点
- Blood perfusion of the kidney
研究概览
简要总结
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels. It has been shown to affect renal function, including electrolyte balance and blood flow, especially in conditions like type 2 diabetes where abnormal glucagon levels are common. The study aims to understand how glucagon affects regional blood flow in the kidneys, specifically the cortex and medulla, and whether these effects are mediated by glucagon receptors.
The study will be conducted on 10 healthy male participants aged 20-60 years. It involves three test days where participants will receive either glucagon, glucagon with a GLP-1 receptor antagonist, or placebo. Blood flow, glomerular filtration rate, and other renal functions will be measured using MRI. The study seeks to clarify whether glucagon's effects on the kidneys are linked to changes in regional blood flow and to determine if these effects are mediated solely by glucagon receptors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Normal health confirmed through; Interview and Medical examination
- •Normal values with respect to blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function tests, and electrolytes
- •Informed consent
排除标准
- •Immunosuppressive treatment in the previous 12 months
- •Alcohol abuse
- •Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the principal investigator, may interfere with glucose metabolism
- •Use of lithium
- •Medical treatment that affects insulin secretion or the renin-angiotensin-aldosterone system
- •Liver disease (ALT > 2x normal value)
- •Renal impairment (serum creatinine > 130 µM and/or albuminuria)
- •Individuals with severe claustrophobia
- •Individuals with MR-incompatible foreign bodies
- •Individuals with hypertension
研究组 & 干预措施
Glucagon+Exendin9-39
干预措施: Glucagon (Drug)
Glucagon
干预措施: Glucagon (Drug)
Glucagon
干预措施: Glucagon+Exendin9-39 (Drug)
Glucagon
干预措施: Sodium chloride (Drug)
Glucagon+Exendin9-39
干预措施: Glucagon+Exendin9-39 (Drug)
Glucagon+Exendin9-39
干预措施: Sodium chloride (Drug)
Sodium chloride (Placebo comparator)
干预措施: Glucagon (Drug)
Sodium chloride (Placebo comparator)
干预措施: Glucagon+Exendin9-39 (Drug)
Sodium chloride (Placebo comparator)
干预措施: Sodium chloride (Drug)
结局指标
主要结局
Blood perfusion of the kidney
时间窗: 7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).
we would like to measure blood perfusion of the kidneys over time
次要结局
- Blood flow of the renal arteries(7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).)
- blood oxygen saturation of the kidneys(7 measurements of 10 minutes each from the start of infusion (time 0) and up to one hour (time 60).)
研究者
Ali Asmar
Chief Physician, Associate Professor, PhD, MD
Bispebjerg Hospital